


200

PTO/SB/21 (01-08)
Approved for use through 01/31/2008, OMB 0651-0031

Under the Pa	perwork Reduction Act of 199	5. no person	is are required to respond to a co				displays a valid OMB control number.	
			Application Number	08/978,632	08/978,632			
TRANSMITTAL			Filing Date	November	November 25, 1997			
FORM			First Named Inventor	Rabbani	Rabbani			
			Art Unit	1635				
the he wood for all correspondence when it is a first first of			Examiner Name	Wollenberg	Wollenberger			
(to be used for all correspondence after initial filing)			Attorney Docket Number	ENz53(C)	ENz53(C)			
Total Number of	Pages in This Submission	l						
ENCLOSURES (Check all that apply)								
Amendmi A A A Extension Express / Informatio Certified of Documen Reply to Incomple	fter Final ffidavits/declaration(s) n of Time Request Abandonment Request on Disclosure Statement Copy of Priority		Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocati Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on C	Address	Lette	Appea of App Appea (Appea Proprio Status Other below) mation I r, 5 For	I Communication to Board eals and Interferences I Communication to TC I Notice, Brief, Reply Brief) etary Information Letter Enclosure(s) (please Identify in the communication to TC in Notice, Brief, Reply Brief) etary Information Letter Enclosure(s) (please Identify in the communication in the commu	
-	SIGN	ATURE (OF APPLICANT, ATTO	DRNEY, C	R AG	ENT	· · · · · · · · · · · · · · · · · · ·	
Firm Name	The Law Offices of Cher	yl H. Agris,	Ph.D., P.C.			·		
Signature	Chusk	J. A.o.	w					
Printed name	Printed name Cheryl H. Agris							
Date	January 9, 2008			Reg. No.	34,086			
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:								
Signature Cleryl W. Agris								
Typed or printed	name Cheryl H. Agris	U				Date	January 9, 2008	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Rabbani et al.

Application No.: 08/978,632

Group Art Unit: 1635

Filed: November 25, 1997

Examiner: A. Bowman

For: NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING

COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES

Confirmation No.: 4638

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL LETTER

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith further references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

Form PTO/SB08a lists US and foreign patent documents and non patent literature that have not been made of record. Some of these foreign patent documents and non-patent literature have been submitted previously. Those submitted herewith are listed below:

Foreign Patents

WO9528494 1995-10-26 Overell et al.

WO9526200 1995-10-05 Williams et al.

WO9508635 1995-03-30 Craig et al.

EP0285057 1988-10-05 Engelhardt et al.

Non-patent documents

VERMA Nature 389: 239-242. 1997

FISHER Neurobiology of Disease 4: 1-22. 1997

DATTA et al. Mol. Cell Biol. 16: 1085-1093. 1996

BENNET et al. pp 13-46 in Methods in Molecular Medicine: Antisense Therapeutics

Ed. S. Agrawal, Humana Press, Inc. Totowa NJ 1996

WANG et al., Proc. Natl. Acad. Sci. USA 92: 3318-3322. 1995

THIMME et al., Virology 211: 296-301. 1995

SUN et al. Proc. Natl. Acad. Sci. USA 92: 7272-7276. 1995

ROSSI, Trends Biotechnol. 13: 301-306. 1995

RAMIREZ et al., Virology 206: 57-68. 1995

MILLER et al., FASEB J. 9: 190-199. 1995

LIMJOCO et al. Virology 208: 75-83. 1995

LEVER British Medical Bulletin 51: 149-166. 1995

LAU et al., Hum Gene Ther. 6: 1145-1151. 1995

BINKLEY et al. Nucleic Acids Res. 23: 3198-3205. 1995

ALLY et al., J. Immunol. 155: 5404-5408. 1995

AGRAWAL et al., Biochem. Pharmacol. 50: 571-576. 1995

ZHOU et al. Gene 149: 33-39. 1994 b

YU et al. Gene Therapy 1: 13-26 1994

VIEILLARD et al. Proc. Natl. Acad. Sci. USA 91: 2689-2693. 1994

NICHOLS et al. Nature 369: 492-493. 1994

LEWIN in Genes V, pp 914-915. 1994

JUNKER et al. Antisense Res. Dev. 4: 165-172. 1994

GRUBER et al. J. Immunol. 152: 5368-5374. 1994

DE YOUNG et al. Biochemistry 33: 12127-12138. 1994

CROOKE, Antisense Res. and Development 4: 145-146. 1994

VLASSOV et al., FEBS Lett. 327: 271-274. 1993

SCHWARTZ et al., Gene 127: 233-236. 1993

SANDIG et al. Gene 131: 255-259. 1993

PALSSON et al. Biotechnology (NY) 11: 368-372. 1993 d

LISZIEWICZ et al., Proc. Natl. Acad. Sci. USA 90: 8000-8004. 1993

LIEBER et al. Methods Enzymol. 217: 47-66. 1993

KOLLER et al. Blood 82: 378-384. 1993

KOLLER et al. BioTechnology 11: 358-363. 1993

HOLLIGER et al. Proc. Natl. Acad. Sci. USA 90: 6444-6448. 1993

FISCHER et al. EMBO J. 12: 573-583. 1993

CRISTIANO et al. Proc. Natl. Acad. Sci. USA 90: 2122-2126. 1993

COX et al. Advan. Enzyme Regul. 33: 27-36. 1993

BALVAY et al. BioEssays 15: 165-169. 1993

ALLAWAY et al. AIDS Res. Human Retroviruses 9: 581-587. 1993

ZAIA et al., Annals of the NY Acad Sci 660: 95-106. 1992

WAGNER et al. Proc. Natl. Acad. Sci. USA 89: 7934-7938. 1992

TAKEDA et al., Proc. Natl. Acad. Sci USA 89: 8180-8184. 1992

SCZAKIEL, J. Virol. 66: 5576-5581. 1992

MUZYCZKA Current Topics in Microbiology and Immunology 158: 97-129. 1992

IZANT in Gene Regulation: Biology of Antisense RNA and DNA pp 183-195. Raven Press, Ltd. New York 1992

HUSSON et al. J. Pediatrics 121: 627-633. 1992

HARRISON et al. Human Gene Therapy 3: 461-469. 1992

FANGER et al. Critical Reviews in Immunology 12: 101-124. 1992

DUMONTET et al. La Revue de Medecine Intern. 13: 460-464. 1992.

CHEN et al. in Antisense Strategies, Annals NY Acad. Sci. 660: 271-273. 1992

BURKLY et al., J. Immunol. 149: 1779-1787. 1992

SCZAKIEL et al., J. Virology 65: 468-472. 1991

PILCH et al. Gene Expression 1: 41-53. 1991

MCBURNEY et al., Nucleic Acids Res. 19: 5755-5761. 1991

LAURENCE et al. J. Virol. 65: 213-219. 1991

JOSHI et al., J. Virol. 65: 5524-5530. 1991

FARUQI et al., Virology 183: 764-768. 1991

DUBENDORFF et al., J. Mol. Biol. 219: 61-68. 1991

CURIEL et al. Proc. Natl. Acad. Sci. USA 88: 8850-8854. 1991

ZIEVE et al. Crit Rev Biochem Mol Biol. 25: 1-46. 1990

YAMASHITA et al. Agric. Biol. Chem. 54: 2801-2809. 1990

SCZAKIEL et al., Biochem Biophys Res Comm 169: 643-651. 1990 f

MAYEDA et al. Nucleic Acids Res. 18: 4671-4676. 1990

KESSLER et al. Advances in Mutagenic Research. Springer Verlag 1: 105-152. 1990

HORTON et al. BioTechniques 8: 528-535. 1990

FISCHER et al. Science 249: 786-790. 1990.

YUO et al. Mol. Cell. Biol. 9: 3429-3437. 1989 a

YOSHIMATSU et al. Science 244: 1346-1348. 1989

WU et al. J. Biol. Chem. 269: 16985-16987. 1989

NITTA et al. Eur. J. Immunol. 19: 1437-1441. 1989

LIEBER et al. Nucleic Acids Res. 17: 8485-8493. 1989

HORTON et al. Gene 77: 61-68. 1989

GATERMANN et al. Mol. Cell Biol. 9: 1526-1535. 1989

NEUMAN DE VEGVAR Nucleic Acids Res. 17: 9305-9318. 1989

COTTEN et al., EMBO J 8: 3861-3866. 1989

BEBENEK et al. J. Biol. Chem. 264: 16948-16956. 1989

SAIKI et al. Science 239: 487-491. 1988

LEIBOLD et al. Proc. Natl. Acad. Sci. USA 85: 2171-2175. 1988

IZANT et al. in Current Communications in Molecular Biology, Cold Spring Harbor Laboratory pp 141-149. 1988

DUNN et al. Gene 68: 259-266. 1988

DAHLBERG et al. in Birnstiel, ed. Springer Verlag, Heidelberg, pp 38-70. 1988

COOK et al. Nucleic Acids Res. 16: 4077-4095. 1988

LEAR et al. J. Biol. Chem. 262: 6500-6505. 1987

KOTANI et al. Nucleic Acids Res. 15: 2653-2664. 1987

STAERZ et al. Proc. Natl. Acad. Sci. USA 83: 1453-1457. 1986

SCHARF et al. Science 233: 1076-1078. 1986

OLD et al., Blackwell Scientific Publications, London, 1986

MORRIS et al. Gene 41: 193-200. 1986

KOZAK Cell 44: 283-292. 1986

JABLONSKI et al. Nucleic Acids Res. 14: 6115-6128. 1986

ERITJA et al. Nucleic Acids Res 14: 8135-8153. 1986

DAVIS et al., Elsevier, NY 1986

ARGOS et al. EMBO J. 5: 433-440. 1986

AGRAWAL et al. Nucleic Acids Res. 14: 6227-6245. 1986

SAIKI et al., Science 230: 1350-1354. 1985

CHU et al. J. Biol. Chem. 260: 10680-10688. 1985

PERBAL, John Wiley & Sons, New York, 1984

MELTON et al. Nucleic Acids Res. 12: 7035-7056. 1984

KALDERON et al., Cell 39: 499-509. 1984 °

DAVANLOO et al., Proc. Natl. Acad. Sci. USA 81: 2035-2039. 1984

CHU et al. Proc. Natl. Acad. Sci. USA 81: 3049-3053. 1984

DUNN et al., J. Mol. Biol. 166: 477-535. 1983

MOUNT Nucleic Acids Res. 10: 459-472. 1982

MANSER et al., Cell: 29: 257-264. 1982

MANIATIS et al., Cold Spring Harbor Laboratory Press, 1982

RUOSLAHTI et al. J. Biol. Chem. 256: 7277-7281. 1981

ANDERSON et al. Nature 290: 754-758. 1981

ROYCHOUDHURY et al. Nucleic Acids Res. 6: 1323-1333. 1979

RIGBY et al. J. Mol. Biol. 113: 237-251. 1977

RAFESTIN et al. FEBS Letters 40: 62-66. 1974

STAVRIANOPOULOS et al. Proc. Natl. Acad. Sci. USA 69: 2609-2613. 1972

SOEIRO et al. J. Mol. Biol. 44: 551-562. 1969

Definitions for "compound", "polymer", "monomer" on 2005-10-19 from

www.cancerweb.ncl.ac.uk

It is respectfully requested that these references be considered by the Patent and Trademark

Office in its examination of the above-identified application and be made of record therein. The

Examiner is also invited to contact the Undersigned if there are any questions concerning this

paper or the attached references.

The Information Disclosure Statement submitted herewith is being filed

[x] after submitting the RCE but before any subsequent Office Action

[] before the mailing date of a first Office Action on the merits

[] after the mailing date of a first Office Action on the merits. Please charge the fee of \$180 to deposit account no. 05-1135.

Respectfully submitted,

Date: 1/9/08

Cheryl M. Agris, Reg. No. 34,086

(914) 712-0093

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		08978632	
Filing Date		1997-11-25	
First Named Inventor Rabb		bani	
Art Unit		1635	
Examiner Name L. Wo		ollenberger	
Attorney Docket Number		Enz-53-C	

CERTIFICATION STATEMENT								
Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):								
	That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).							
OR	OR							
	That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).							
	See attached certification statement.							
Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.								
	None							
SIGNATURE A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.								
Sig	nature	Cherry H. Aoris	Date (YYYY-MM-DD)	2008-01-09				
Nai	ne/Print	Cheryl H Agris	Registration Number	34086				
Thi	s collection of info	(and by the USPTO to process) an a	and 1.98. The information is required in the property of the p	red to obtain or retain a benefit by the rned by 35 U.S.C. 122 and 37 CFR				

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**